Investigator

Shiki Takamura

Team Leader · RIKEN IMS, Laboratory for Immunological Memory

STShiki Takamura
Papers(1)
Histopathological sub…
Collaborators(8)
Tomoyuki OtaniChiho MiyagawaHidekatsu NakaiHisamitsu TakayaKosuke MurakamiMasaki MandaiNoriomi MatsumuraRyusuke Murakami
Institutions(2)
Kindai UniversityKyoto University

Papers

Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging

We have established 4 histopathologic subtyping of high-grade serous ovarian cancer (HGSOC) and reported that the mesenchymal transition (MT) type has a worse prognosis than the other subtypes. In this study, we modified the histopathologic subtyping algorithm to achieve high interobserver agreement in whole slide imaging (WSI) and to characterize the tumor biology of MT type for treatment individualization. Four observers performed histopathological subtyping using WSI of HGSOC in The Cancer Genome Atlas data. As a validation set, cases from Kindai and Kyoto Universities were independently evaluated by the 4 observers to determine concordance rates. In addition, genes highly expressed in MT type were examined by gene ontology term analysis. Immunohistochemistry was also performed to validate the pathway analysis. After algorithm modification, the kappa coefficient, which indicates interobserver agreement, was greater than 0.5 (moderate agreement) for the 4 classifications and greater than 0.7 (substantial agreement) for the 2 classifications (MT vs. non-MT). Gene expression analysis showed that gene ontology terms related to angiogenesis and immune response were enriched in the genes highly expressed in the MT type. CD31 positive microvessel density was higher in the MT type compared to the non-MT type, and tumor groups with high infiltration of CD8/CD103 positive immune cells were observed in the MT type. We developed an algorithm for reproducible histopathologic subtyping classification of HGSOC using WSI. The results of this study may be useful for treatment individualization of HGSOC, including angiogenesis inhibitors and immunotherapy.

1Works
1Papers
8Collaborators
Carcinoma, Non-Small-Cell LungLung NeoplasmsCell Line, TumorDrug Resistance, NeoplasmNeoplasmsOvarian NeoplasmsCystadenocarcinoma, SerousPrognosis

Positions

2022–

Team Leader

RIKEN IMS · Laboratory for Immunological Memory

2008–

Assistant Professor

Kindai University Faculty of Medicine · Department of Immunology

Country

JP